-+ 0.00%
-+ 0.00%
-+ 0.00%

Cosciens Biopharma Q3 2026 net loss widens 89% to USD 3.4 million

PUBT·11/13/2026 14:34:59
Listen to the news
Cosciens Biopharma Q3 2026 net loss widens 89% to USD 3.4 million
  • Cosciens Biopharma’s Q3 2026 net loss widened 89% year-over-year to USD 3.4 million, partly due to a USD 2 million impairment.
  • Revenue rose 67% year-over-year to USD 2.5 million, primarily reflecting higher active ingredient sales volumes.
  • For the nine months ended September 30, 2026, net income swung to USD 7.1 million, primarily due to improved discontinued operations.
  • The September acquisition of Nualtis carried a USD 15 million base price, with its Rizatriptan launch expected in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosciens Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130934PRIMZONEFULLFEED9877256) on November 13, 2026, and is solely responsible for the information contained therein.